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LIPOPOLYSACCHARIDE is an inflammatory agent and inter-
leukin-1 is a cytokine. Their pro-inflammatory effects
may be mediated by prostanoids produced by indu-
cible cyclooxygenase-2. The aim of this study was to
determine  the  prostanoids  produced  by  lipopoly-
saccharide and  interleukin-1  stimulated enterocytes
through the cyclooxygenase-1 and 2 pathways. Cul-
tured  enterocytes  were  stimulated  with  lipopoly-
saccharide  or  interleukin-1b with  and  without
cyclooxygenase  inhibitors.  Low  concentrations  of
indomethacin  and  valerylsalicylic  acid  (VSA)  were
evaluated  as  cyclooxygenase-1  inhibitors  and  their
effects  compared  with  the  effects  of  a  specific
cyclooxygenase-2 inhibitor,  SC-58125. Prostaglandin
E2,  6-keto  prostaglandin  F1a ,  prostaglandin  D2 and
leukotriene  B4 levels  were  determined  by  radio-
immunoassay.  Immunoblot  analysis  using  isoform-
specific  antibodies  showed  that  the  inducible
cyclooxygenase  enzyme  (COX-2)  was  expressed  by
4 h  in  LPS  and  IL-1b treated  cells  while  the  con-
stitutive COX-1 remained unaltered in its expression.
Interleukin-1b and lipopolysaccharide stimulated the
formation of all prostanoids compared with untrea-
ted  cells,  but  failed  to  stimulate  leukotriene  B4.
Indomethacin at 20 m M concentration, and VSA inhib-
ited lipopolysaccharide and interleukin 1b stimulated
prostaglandin  E2,  but  not  6-keto  prostaglandin  F1a
formation.  SC-58125  inhibited  lipopolysaccharide
and  interleukin-1b stimulated  6-keto  prostaglandin
F1a but  not  prostaglandin  E2 release.  The  specific
cyclooxygenase-2  inhibitor  also  inhibited  lipopoly-
saccharide produced prostaglandin D2 but not inter-
leukin-1b stimulated  prostaglandin  D2 While  SC-
58125  inhibited  basal  6-keto  prostaglandin-F1a
formation  it  significantly  increased  basal  prosta-
glandin  E2 and  prostaglandin  D2 formation.  As  SC-
58125 inhibited  lipopolysaccharide and interleukin-
1b induced 6-keto prostaglandin F1a production but
not  prostaglandin  E2 production,  it  suggests  that
these  agents  stimulate  prostacyclin  production
through  a  cyclooxygenase-2  mediated  mechanism
and  prostaglandin  E2 production  occurs  through  a
cyclooxygenase-1  mediated  mechanism.  Prostaglan-
din D2 production appeared to be variably produced
by cyclooxygenase-1 or cyclooxygenase-2, depending
on the stimulus.
Key  words:  Cytokines,  Eicosanoids,  Cyclooxygenase
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Introduction
Metabolism of arachidonic acid occurs by three major
enzymatic  pathways;  cytochrome  P450,  lipooxyge-
nase and cyclooxygenase.1,2 Prostanoid production in
the cyclooxygenase system is the result of the activity
of  at  least  two  prostaglandin  H  synthase  (cycloox-
ygenase, COX) enzymes, COX-1 and COX-2.3 COX-1 is
a  constitutive  enzyme,  present  in  low  levels,  and
believed  to  produce  continuously  present  cytopro-
tective prostanoids.4,5 COX-2 is inducible in response
to  a  variety  of  stimulants  including  mitogens  and
inflammatory agents and is believed to produce pro-
inflammatory prostanoids.6,7
Limited  information  exists  concerning  the  role
specific eicosanoids play in inflammatory processes
studied in vivo and why, in vitro, certain cell lines
produce certain eicosanoids in response to various
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role  of  eicosanoids  in  intestinal  inflammation,  we
examined the effect of Clostridium difficile toxin on
the production of eicosanoids by a  human  colonic
cancer cell line (Caco-2).8 The increased eicosanoid
production stimulated by Clostridium difficile toxin
was characterized by large increases in prostaglandin
E2 (PGE2)  and  6-ketoprostaglandin-F1a (6KPGF1a )
production  but  not  leukotriene  B4 (LTB4).  In  a
subsequent  study  in  the  same  cell  line,9 trinitro-
benzene  sulphonic  acid  (TNB),  a  hapten  which
produces experimental colitis, produced a response
characterized  by  the  release  of  6KPG  F1a and
LTB4.
Working  with the  hypothesis that  certain prosta-
noids were produced by COX-1 and others by COX-
2,  attempts  were  made  to  discern  the  relative
contributions  of  COX-1  and  COX-2  to  prostanoid
formation by intestinal epithelial cells stimulated by
pro-inflammatory agents. Based on in vitro data that
microsomal  COX-1  enzyme  is  inhibited  by  low
concentration  indomethacin  and  COX-2  inhibition
requires greater concentrations of indomethacin by a
factor  of five,10,11 we studied the relative contribu-
tions of COX-1 and COX-2 to prostanoid formation.8
Evaluation of Caco-2 cells stimulated by Clostridium
difficile toxin demonstrated that  low concentration
indomethacin failed to  inhibit  Clostridium  difficile
toxin  stimulated  prostanoid  formation  while  high
concentration indomethacin did, consistent with the
concept that Clostridium difficile stimulated prosta-
noid  formation  through  a  COX-2  mediated
process.
We pursued the issue further by evaluating the role
of COX-1 and COX-2 in TNB stimulated Caco-2 cells.9
Both low (20m M) and high (100m M) concentration
indomethacin inhibited resting  and TNB  stimulated
formation  of  all  prostanoids. As  low  concentration
indomethacin  inhibited TNB  stimulated  prostanoid
formation, we were unable to confirm the proposed
role of COX-2 in mediating intestinal epithelial cell
prostanoid  formation  in  response  to  inflammatory
stimuli  utilizing  this  methodology.  In  a  preliminary
study a specific COX-2 inhibitor, NS39812 inhibited
enterocyte  prostacyclin  formation  stimulated  by
proinflammatory  agents,  but  did  not  significantly
change the increase in PGE2.13 In the present study,
the  specific  COX-2  inhibitor,  SC58125,14 was  com-
pared with both low dose indomethacin and valer-
ylsalicylic acid  (VSA),15 a  salicylate  ester  with  con-
siderable  specificity  toward  COX-1,  to  attempt  to
determine  the  relative  contributions  of  COX-1  and
COX-2 to prostanoid formation by an epithelial cell
line.
Lipopolysaccharide (LPS) is an inflammatory agent
which  induces interleukin-1 (IL-1)16 and prostanoid
formation17 and alters intestinal permeability,18 and
mitogenesis,19 and causes the production by intesti-
nal cells of a heat shock protein.20 Interleukin-1, a
pro-inflammatory cytokine which is capable of stim-
ulating arachidonic acid metabolism21 has been impli-
cated as an inflammatory mediator in the intestine.22
IL-1 has been shown to increase prostanoid synthesis
by a COX-2 mediated mechanism.21 It is possible that
this pro-inflammatory cytokine, released within intes-
tinal  tissues,  could  mediate  prostanoid  formation
produced by pro-inflammatory agents. In this study,
we evaluated the effects of LPS and IL-1 on COX-1 and
COX-2  eicosanoid production in an enterocyte  cell
line.
Materials and Methods
Cell culture
The non-transformed rat enterocyte cell line, derived
from  distal  ileum,  IEC-18  (American  Type  Culture
Collection, Rockville, MD) was utilized in all experi-
ments employing culture techniques described pre-
viously.8,9 Briefly, the cells were maintained in Eagle’s
minimum  essential  medium  (MEM)  supplemented
with 10% fetal bovine serum containing gentamicin
(0.1mg/ml) and 1% MEM  nonessential amino acids
(Sigma, St Louis, MO). The cells were grown in a 37°C,
humidified,  5%  CO2 incubator  and  maintained  by
weekly  passage. The  cells  were  plated  on  six-well
tissue culture plates (Costar, Cambridge, MA) at 2 3
105 cells  per  well  and  allowed  to  grow  to  100%
confluence. The cell morphology was evaluated by
routine phase microscopy.
Materials and protocol
The cells were washed with KRB buffer and exposed
for 4h to LPS or IL-1b dissolved and diluted in 95%
oxygenated  KRB  buffer.  The  lipopolysaccharide
employed  was  Escherichia  coli lipopolysaccharide,
CO  111:B4  (Sigma,  St  Louis,  MO).  The  human
recombinant IL-1b was obtained from Merck Du Pont
Laboratories,  Glenolden,  PA.  Indomethacin  (Sigma
20m M), VSA (Cayman, Ann Arbor, MI, 50m M) and SC-
58125  (50m g/ml)  were  dissolved  in  5%  sodium
carbonate solution and diluted in KRB buffer imme-
diately  before  use  and  added  to  the  wells.  The
concentration  of  indomethacin  was  chosen  to
attempt to produce inhibition of COX-1 but not COX-
2 enzyme activity.10,11 To evaluate the effect of the
COX  inhibitors,  the  cells  were  pre-treated  with
indomethacin, VSA or SC-58125 in 1ml fresh tissue
culture  media  for  1h  prior  to  washing  the  cells.
Control cells and cells exposed to LPS or IL-1b were
similarly  treated  with  fresh  media  for  1h.  At  the
conclusion of the experiments the cells and buffer
were collected and frozen at – 80°C until the protein
assays were performed.
W . E. Longo et al.
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Western blot analysis
Cells were seeded into 35mm dishes (1.5 3 106/dish)
and  grown  to  confluency  for  2  days. The  cultures
were rinsed with serum-free medium and incubated
with media alone or with IL-1 B or LPS for 8h. At the
conclusion of the experiments the cells were lysed
with  1%  Triton  X-100,  120mM  sodium  chloride,
25mM HEPES (pH 7.4), 1mM phenylmethylsulfonyl
fluoride,  10m /ml  leupeptin,  10m g/ml  apoprotinin
and 10m g/ml antipapain. After 30min, the extracts
were centrifuged at 12000 3 g for 10min and the
supernatants  solubilized  with  SDS-PAGE  buffer
(68mM Tris-HCI, pH 6.8, 5%  B-mercaptoethanol, 2%
SDS, and 10%  glycerol). The samples were boiled for
5min and equal amounts were applied to a 10% SDS-
polyacrylamide  gel.  Proteins  were  transferred  to
nitrocellulose and then incubated overnight in Tris-
buffered saline, 0.2% Tween-20, and 10% non-fat dry
milk (BLOTTO). The membranes were incubated with
a rabbit anti-serum generated against murine COX-2
(1:1000) or sheep COX-1 (1:1000). Following a 3-h
incubation  at  37°C,  the  membranes  were  washed
with BLOTTO and incubated with goat anti-rabbit IgG
conjugated to horseradish peroxidase (1:1000, Cap-
pel)  for  30min  at  37°C.  Immunoreactive  proteins
were  visualized  using  the  enhanced  chemilumine-
sence (ECL®; Amersham) method.
Eicosanoid determination
To determine the cell protein concentration per well
the wells were thawed and washed with KRB buffer.
The  cells  were  freed  by  incubation  with  1%   col-
lagenase solution for 20min. The cells were scraped
from the wells and centrifuged at 200 3 g for 20min
and washed with KRB. Protein was determined by the
method of Bradford23 on cell specimens which were
solubilized with 0.1 N NaOH for 1h at 37°C and then
sonicated for 10s. Bovine albumin was employed as
the standard. PGE2, 6-KPGF1a , PGD2 and leukotriene
B4 (LTB4)  assays  were  performed  on  the  buffer
solutions in duplicate without separation by a com-
petitive enzyme assay which utilizes an acetylcholi-
nesterase  tracer  (Cayman,  Ann  Arbor,  MI).8,9 The
eicosanoid concentrations were determined by spec-
trophotometric  analysis  after  addition  of  Ellman’s
reagent  and  comparison  to  a  standard  curve. The
concentrations  of  eicosanoids  were  expressed  as
picograms per milligram cell protein.
Statistical analysis
The  data  is  presented  as  mean  ±  SEM.  Statistical
analysis  was  performed  by  analysis  of  variance.
Differences between groups was determined by the
least  significant  difference. As used throughout  the
manuscript ‘significant’ indicates P < 0.05.
Results
Western  blotting  of  resting  cells  (medium  alone)
faintly  demonstrated  detectable  COX-1  and  COX-2
protein. When cells were incubated with LPS or IL-1b
for periods of up to  24h, there was no change in
expression  of  COX-1  protein  (data  not  presented).
However,  by 8h  of  LPS  or  IL-1b treatment,  COX-2
expression was increased (Fig. 1). Prestained molec-
ular weight markers were run on the same gels and
the COX immunoreactive bands shown corresponded
to proteins approximately 70kDa in size consistent
with COX enzymes.
LPS  and  IL-1b produced  concentration  related
increases in PGE2, 6KPGF1a and PGD2 formation by
IEC-18 cells. Representative  data demonstrating  the
effect of IL-1b on PGD2 formation is presented in Fig.
2.  IL-1b (0.01,  0.1,  1.0,  10  and  100  units/ml)
Prostanoid formation in the cydooxygenase system
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FIG. 1. LPS and IL-b stimulated COX-2 protein expression.
IEC-18 cells were seeded into 35mm dishes and grown for 2
days at which time they were incubated with LPS or IL-1b .
Control cells received medium alone during the incubation
period. Extracts of the cells were prepared  by SDS-PAGE,
blotted  onto  nitrocellulose  membranes,  and  probed  with
antibody specific for COX-2. COX-1 protein was very faintly
visualized and no apparent increase was produced by LPS or
IL-1b (data not presented).
FIG.  2.  The  effect  of  IL-1b on  PGD2 formation.  Each  bar
represents the  mean  ± SEM  of six  values obtained  from
duplicate measurements of samples from six wells. Asterisk
indicates that the experimental value is significantly different
from the control value.L
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produced maximal responses in prostanoid formation
at 10 units/ml. LPS (0.01, 0.1, 1.0, 10 and 100m g/ml)
produced significantly greater prostanoid levels when
100m g/ml  were  administered  than  when  10m g/ml
was evaluated. Neither LPS or IL-1b in the concentra-
tions  and  time  intervals  employed  in  this  study
significantly changed LTB4 production by IEC-18 cells
(Fig. 3). Also evaluation of LTB4 levels in experiments
associated  with  indomethacin,  VSA  or  SC58125
administration  with  and  without  LPS  or  IL-1b was
associated with no significant changes in LTB4 forma-
tion (data not presented).
As seen in Fig. 4, LPS (100m g/ml) and IL-1b (10
units/ml) stimulated PGE2 production by IEC-18 cells
compared with control values. VSA and indomethacin
(20m M) significantly decreased LPS and IL-1b stimu-
lated  PGE2 production  while  the  specific  COX-2
inhibitor,  SC-58125  (50m g/ml)  did not  significantly
alter  LPS  or  IL-1b stimulated PGE2 production and
significantly increased basal PGE2 production.
The pro-inflammatory agent LPS and the cytokine
IL-1b both significantly increased prostacyclin forma-
tion as evidenced by increases in the stable metabo-
lite of prostacyclin, 6-KPGF1a (Fig. 5). Neither indom-
ethacin (20m M) or VSA significantly altered basal or
stimulated 6KPGF1a formation; however, the selective
COX-2 inhibitor SC-58125 significantly decreased the
formation  of  6KPGF1a in  response  to  the  pro-
inflammatory agents. These results and the results of
the evaluation of PGE2 formation suggest that PGE2 is
produced by COX-1 and prostacyclin is produced by
COX-2 in IEC-18 cells. The results also suggest that an
inflammatory  stimulus  such  as  endotoxin  and  a
cytokine such as IL-1b may stimulate the formation of
a  prostanoid  (PGE2)  produced  by  the  COX-1
pathway.
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FIG. 3. The effect of LPS and IL-1b on LTB4 production by IEC-
18  cells.  Neither  LPS  (100m g/ml)  or  IL-1b (10units/ml)
stimulated  LTB4 formation  compared with  control  values.
Each bar represents the mean ± SEM of six values obtained
from the mean of duplicate measurements from six wells
containing 1 3 105 confluent cells.
FIG. 4. The effect of indomethacin, VSA, a specific COX-1
inhibitor and SC-58125, a specific COX-2 inhibitor, on PGE2
formation in response to LPS (100m g/ml) and II-LB (10 units/
ml). Indomethacin (20m M) and VSA inhibited the increase in
PGE2 formation produced by LPS and IL-1b ; however SC-
558125 (50m g/ml) did not. Each bar represents the mean ±
SEM  of  six  values  obtained  from  the  mean  of  duplicate
measurements  from  six  wells  of  confluent  ileal  mucosal
cells.  One  asterisk  indicates  that  the  stimulated  value  is
significantly different (P< 0.05) from the resting value and #
indicates that the inhibitor significantly  altered the results
produced by LPS or IL-1b
FIG. 5. The effect of indomethacin (20m M), VSA (50m M) and
SC-58125 (50m g/ml) on  LPS and  IL-1b stimulated 6KPGF1
i
formation.  SC  58125,  the  specific  COX-2  inhibitor  sig-
nificantly decreased resting and stimulated 6KPGF1
i forma-
tion while indomethacin and VSA did not. Each bar repre-
sents the mean ± SEM of six values obtained for the mean of
duplicate  measurements  from  six  wells  of  IEC-18  enter-
ocytes. One asterisk indicates that the stimulated value is
significantly different (P< 0.05) from the resting value and #
indicates that the inhibitor significantly  altered the results
produced by LPS or IL-1b .*
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PGD2 is a prostanoid involved in the production of
inflammation in various systems24 and has been found
to  be  a  major  prostanoid  produced  by  intestinal
epithelial  cells  in  response  to  mitogenic  stimuli.25
Both LPS and IL-1b increased PGD2 production (Fig.
6).  Indomethacin  did  not  significantly  alter  LPS
stimulated  PGD2 concentrations;  however,  it  did
significantly inhibit IL-1b stimulated PGD2 levels. The
specific  COX-2  inhibitor  SC-58125  and  the  COX-1
inhibitor VSA decreased the PGD2 response produced
by  LPS. The  COX-2  inhibitor  markedly  augmented
PGD2 production by resting IEC-18 cells and by IL-1b
stimulated cells. The COX-1 inhibitor, VSA, decreased
the PGD2 response produced by LPS and IL-1b . LPS
appeared to increase PGD2 formation through COX-1
and  COX-2  metabolic  pathways  while  IL-1b stimu-
lated PGD2 formation produced by COX-1.
Discussion
The specific role that individual prostanoids play in
the  physiologic  functions  of  mucosa  or  in  the
pathologic  processes  involving  intestinal  mucosa
including  inflammation  is  unknown.  The  general
hypothesis presently directing many research efforts
is that COX-1, a constitutive enzyme, produces basal
cytoprotective prostanoids; and that COX-2, an indu-
cible enzyme responding to pro-inflammatory agents
and  mitogens,  produces  prostanoids  involved  in
inflammation and replication of mucosal cells.2,5,7The
availability of specific COX-1 and COX-2 inhibitors,
which have a high degree of specificity against pure
enzyme  preparations, should enable the determina-
tion of which enzyme produces which prostanoid in
response to a specific stimulus.
In two previous studies employing enzyme prepara-
tions  there  was  some  dose  specificity,  with  low
concentrations  of  indomethacin  inhibiting  COX-1
while COX-2 inhibition required much higher concen-
trations.10,11 In  another  report  low  concentration
indomethacin  appeared  to  be  an  inhibitor  of  both
COX-1  and  COX-2.12 In  this  study  we  chose  to
preincubate  the  cells  with  the  inhibitors  prior  to
exposing the cells to the pro-inflammatory agents. In
other  studies,  COX-2,  but  not  COX-1  containing
J774.2 macrophages preincubated with indomethacin
were resistant to indomethacin.26 Additionally, other
reports  have  demonstrated  that  even  without  pre-
incubation,  Chinese  hamster  ovary  cells  stably
expressing COX-2 but not COX-1, were resistant to
indomethacin.27 The inhibition of  PGE2 production
but not 6KPGF1a formation by 20m M indomethacin
and VSA produced in the present study supports the
premise  that  COX-1,  but  not  COX-2  activity  was
inhibited by low dose indomethacin.
COX-1 and COX-2 produce similar products (PGG1
and PGH 2)7 but  exist  in separate  cellular  compart-
ments.28 In a previous study employing pure COX-1
or COX-2 enzyme, both enzymes produced PGE2.12
When COS-1  cells  were transfected with COX-1 or
COX-2  containing  expression  vector,  both  trans-
formed cell lines produced comparable basal levels of
PGE2, PGD2 and PGF2a from arachidonic acid.10 The
effect  of  specific  COX-1  and  COX-2  inhibitors  on
resting  prostanoid production in the  present  study
also suggests that unstimulated prostanoid formation
was produced primarily by COX-1 activity. Inhibition
of COX-2 enzyme activity by SC-58125 significantly
increased basal PGE2 and PGD2 formation. This result
suggests that COX-2 inhibition in resting IEC-18 cells
drives arachidonic acid into COX-1 produced PGE2. It
is unclear whether this is the result  of a low level
COX-2  protein continuously  present or  due  to  low
level induction of COX-2 produced by cell manipula-
tion and culture techniques. Utilizing Western blotting
the COX-2 protein was identified in resting cells. In
previous studies evaluating isolated human gall blad-
der  mucosal  cells,  COX-2  protein  expression  was
markedly increased by lysophosphatidylcholine; how-
ever,  resting  gall  bladder  mucosal  cells  faintly
expressed COX-2 protein.29
It has been an important consideration in eicosa-
noid  metabolism  that  cyclooxygenase  inhibition
directs arachidonic acid into the lipooxygenase path-
way.30 This  phenomenon  may  be  occurring  in  the
Prostanoid formation in the cydooxygenase system
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FIG. 6. The effect of indomethacin, VSA and SC-58125 on the
formation  of  PGD2 stimulated  by  LPS  and  IL-1b .  LPS
stimulated PGD2 formation was inhibited by SC-58125 and
VSA but not by indomethacin while IL-1b stimulated PGD2
formation was inhibited by indomethacin and VSA but not
SC-58125. When the COX-2 inhibitor was administered to
resting or IL-1b stimulated cells an exaggerated  increased
response in PGD2 production occurred. Each bar represents
the mean ± SEM of six values obtained from six wells of
confluent  rat  enterocytes.  One  asterisk  indicates  that  the
stimulated value is significantly different (P< 0.05) from the
resting value and # indicates that the inhibitor significantly
altered the results produced by LPS or IL-1b .present study with COX-2 inhibition directing arachi-
donic  acid  metabolism  into  the  COX-1  metabolic
pathway associated with enhanced PGE2 and PGD2
formation.  Alternatively  it  is  possible  that  COX-2
produced prostacyclin produces a negative feedback
mechanism, inhibiting COX-1 from producing PGE2
and PGD2. Future studies will need to be performed
evaluating  the effect  of  specific  COX-1  inhibitors15
and  exogenous  prostacyclin  on  the  response  of
resting IEC-18 cells to SC-58125.
An important finding in the present study suggests
that  both  LPS  and  IL-1b stimulate  PGE2 formation
through a COX-1 mediated process. COX-1 produced
products were increased in response to stimulation
by  inflammatory  agents.  It  is  unlikely  that  the
inflammatory  agents  increased  constitutive  COX-1
protein formation, as it was not evidently induced as
evaluated by Western immunoblotting and as it has
generally not been inducible by cytokines;2 however,
there does seem to be stimulation of COX-1 enzyme
activity.
These  results  suggest  that  inflammatory  or  mito-
genic  stimuli  which  induce  COX-2  but  not  COX-1
expression  do  not  necessarily  produce  prostanoids
exclusively through  COX-2 activity. Prostacyclin for-
mation in response to inflammatory stimuli appeared
to be primarily associated with COX-2 activity. The
relationship  that  resulted  in  comparable  responses
regarding  PGE2 and  prostacyclin  formation  being
produced by LPS and IL-1b was not present when the
PGD2 response was evaluated. LPS stimulated PGD2
appeared to be produced by COX-1 and COX-2 while
the IL-1b response appeared to be mediated by COX-
1. SC-58125 again produced an exaggerated response
with  increased  production  of  PGD2 in  association
with the purported COX-1 stimulant, IL-1b .
Recently, overexpression of COX-2 has been asso-
ciated  with  epithelial  malignancy.31 In  studies  of
human  colorectal  cancer,  COX-2  is  increased  in
approximately  90%  of  the  cancers  and  40%  of
premalignant  colorectal  adenomas,  but  it  is  not
expressed  in  non-tumour  colon  tissue.32 Cycloox-
ygenase inhibitors that block the activity of COX-2 are
associated  with  a  decreased  incidence  of  colon
cancer.31 Sulindac a COX inhibitor produced polyp
regression in patients with familial polyposis.33 The
availability of specific COX-2 inhibitors may result in
improved  effectiveness  of  these  drugs  in  altering
carcinogenesis, while decreasing their side effects.
The  results  produced  in  this  study  suggest  that
increased  production  of  a  specific  prostanoid  in
response to a pro-inflammatory agent or a cytokine
may not be due to stimulation of inducible COX-2.
Delineating  which  enzymatic  pathway  produces
which prostanoids in response to various inflamma-
tory, mitogenic or cytoprotective stimuli may improve
our understanding of the role of prostanoids in health
and disease.
Other recent studies have found that in the same
cell line, different stimuli produced different prosta-
noids.34 The mechanism by which differential prosta-
noid or leukotriene formation occurs is not known. It
is  possible  that  a  specific  stimulus  may  alter  the
activity  of  one  of  the  rate  controlling  enzymes  in
arachidonic  acid  formation,  secretory  14kDa  phos-
pholipase A2 or cytoplasmic 85kDa phospholipase A2
resulting in the generation of prostanoids through a
specific  synthetic  pathway  which  generates  one
prostanoid rather than another.35 As suggested in the
present study, it is possible that a cytokine stimulates
COX-1  or  COX-2  to  generate  specific  prostanoid
species.  Erdbrugger  et  al.34 proposed  that  cells
contain  multiple  compartments36 that  differentially
express  the  phospholipase,  COX,  isomerase  and
synthase  enzymes responsible  for  producing  a spe-
cific  prostanoid  and  also  that  these  compartments
may  present  receptors  for  specific  stimuli.  Further
research will be required to determine how and why
cells make one prostanoid rather than another.
W . E. Longo et al.
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